NCT05601778

A Study of HSK31858 in Participants with Non-Cystic Fibrosis Bronchiectasis

Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of HSK31858 in Participants with Non-cystic Fibrosis Bronchiectasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 226 (actual)
• Sponsor: Haisco Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in non-cystic fibrosis bronchiectasis (NCFBE) participants.

Conditions

• Non-cystic Fibrosis Bronchiectasis (NCFBE)

Interventions

Type	Name	Description
DRUG	HSK31858	HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 24-week treatment period in patients with non-cystic fibrosis bronchiectasis
DRUG	placebo	the placebo comparator of study

Timeline

• Start date: 2022-12-06
• Primary completion: 2024-03-29
• Completion: 2024-06-07
• First posted: 2022-11-01
• Last updated: 2024-09-26

Locations

1 site across 1 country: China